Deintensification Doubled But Still Lags in Overtreated Older Diabetics

This large electronic health record cohort quantifies how often clinicians add or subtract diabetes drugs in older adults relative to individualized glycemic goals, exposing persistent overtreatment and undertreatment gaps relevant to pharmacist-led medication optimization.

sulfonylureasinsulinGLP-1 receptor agonistsSGLT-2 inhibitorsmetformintype 2 diabetesolder adultsdeintensificationdeprescribingHbA1cADA guidelinescohort studyovertreatment Endocrinology / Diabetes / Obesity

Background Information

Exploring medication changes for older adults with diabetes.

Understanding medication changes in older adults can improve outcomes and reduce adverse effects. No abstract available; key results cannot be determined. The study appears to explore diabetes medication management, not opioid stewardship. Study lacks accessible details due to missing abstract.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Le P, Guo N, Misra-Hebert AD, Casacchia NJ, Yue Y, Gasoyan H, Taksler GB, Rothberg MB

Citation: Le P, Guo N, Misra-Hebert AD, et al. Intensification and Deintensification of Diabetes Medications Among Older Adults With Type 2 Diabetes. JAMA internal medicine. 2026. doi:10.1001/jamainternmed.2026.3483

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →